RoACTEMRA.com

ACR 2010: Key ACTEMRA/RoACTEMRA abstracts

The American College of Rheumatology (ACR) 74th Annual Scientific Meeting took place in Atlanta, USA on 6–11 November 2010, bringing together approximately 14,000 delegates from around the world. Please click on abstract numbers or titles in the table below to view key ACTEMRA/RoACTEMRA abstracts presented at the congress.

The next ACR congress will take place on 4–9 November 2011 in Chicago USA. Please click here to go to the ACR annual meeting home page.

ACTEMRA/RoACTEMRA (Tocilizumab) oral presentations

Abstract #	Title	Presenter
1434	Tocilizumab in Patients With Systemic Juvenile Idiopathic Arthritis: Efficacy Data From the Placebo-Controlled 12-Week Part of the Phase 3 TENDER Trial	F De Benedetti
1441	Lipid and Inflammation Parameters: A Translational, Randomized Placebo-Controlled Study to Evaluate Effects of Tocilizumab: The MEASURE Study	I McInnes
2262	Tocilizumab (TCZ) Plus Methotrexate (MTX) in Rheumatoid Arthritis (RA) Patients (pts) Who Increased TCZ Dose From 4 mg/kg to 8 mg/kg: LITHE Radiographic and Safety Data	R Fleischmann
701	Tocilizumab in Refractory Adult Still’s disease: A Cohort Study	X Puéchal
629	TNF and IL-6 Differentially Regulate the Production of DKK-1, a Master Regulator of Bone Remodelling, by Fibroblast-Like Synoviocytes	N Yeremenko

 

ACTEMRA/RoACTEMRA (Tocilizumab) poster presentations

Abstract #	Title	Presenter
56	Comparison of the Efficacy of Tocilizumab and TNF-α Inhibitors on the DAS28 in "Real Life" Conditions in Rheumatoid Arthritis (RA) Patients After DMARD Failure	J Kaufmann
82	Relative Importance of Patient’s Opinion and Physician’s Criteria of Disease Activity Versus Information of Disease Duration and Rheumatologist Type of Exercise for Treatment Decision in Rheumatoid Arthritis: DUO Study	M Dougados
120	Baseline CRP Predicts Early Improvement in Synovitis, Osteitis and Erosion on MRI in RA Patients Treated With Tocilizumab: Results From the ACT-RAY MRI Substudy	O Troum
125	Discriminative Power of Different Combinations of Bones and Joints for Assessing Change in Rheumatoid Arthritis With MRI: Results Based on Pooled Data from Four Multisite Clinical Trials	C Peterfy
378	Characterisation of Laboratory Parameters in Long-Term Extension Studies of Tocilizumab in Rheumatoid Arthritis	W Rigby
384	First Experiences With Pregnancies in RA Patients (pts) Receiving Tocilizumab (TCZ) Therapy	A Rubbert-Roth
399	Post-Marketing Surveillance Program of Tocilizumab for RA in Japan - Interim Analyses of 3,881 Patients	T Koike
411	Safety and Tolerability of Tocilizumab in Long-Term Extension Studies of Rheumatoid Arthritis	M Genovese
1031	Factors Associated With Upper and Lower Gastrointestinal Perforation in a Cohort of Patients With Rheumatoid Arthritis	J Curtis
1109	Improved Disease Control in Response to Tocilizumab Therapy is Accompanied by Decreased Platelet Reactivity in Patients With Rheumatoid Arthritis	P MacMullan
1474	Biochemical Markers of Bone Balance (CTX-I/Osteocalcin) Improve With Tocilizumab Treatment in a Population of RA Patients With an Inadequate Response to Anti-TNF Therapy	M Karsdal
1788	A Study to Evaluate the Effectiveness and Safety of the Interleukin-6 (IL-6) Receptor Antagonist Tocilizumab After 4 and 24 Weeks in Patients With Active Rheumatoid Arthritis (RA) - Final Effectiveness Results of the TAMARA Study	A Rubbert-Roth
1793	Clinical, Structural and Functional Remission in the Treatment of Rheumatoid Arthritis With Tocilizumab in Daily Clinical Practice - REACTION-2 Study	T Takeuchi
1800	Drug Free Remission After Cessation of Tocilizumab (ACTEMRA) Monotherapy (DREAM Study)	N Nishimoto
1808	Efficacy and Safety of Tocilizumab in Patients With Moderate to Severe Active RA and a Previous Inadequate Response to DMARDs: The ROSE Study	Y Yazici
1819	LITHE: Tocilizumab (TCZ) Inhibits Radiographic Progression and Improves Physical Function in Rheumatoid Arthritis (RA) Patients (pts) at 3 Years With Maintenance of Clinical Efficacy Over Time	J Kremer
1820	Long-Term Efficacy of Tocilizumab (TCZ) in Patients (Pts) With Rheumatoid Arthritis (RA) Treated up to 3.7 Years	M Khraishi
1823	Multiple Regression Analysis on the Clinical Parameters Associating With Clinical, Structural and Functional Remission at 52 Weeks in RA Patients Treated With Anti-IL-6 Receptor Antibody, Tocilizumab – REACTION-2 Study	T Takeuchi
1840	Tocilizumab Treatment in Patients With Rheumatoid Arthritis and an Inadequate Response to DMARDs and/or TNF Inhibitors: ACT-SURE Preliminary Results	V Bykerk

 

The abstracts included in this list have been highlighted as interesting information related to treatment with tocilizumab presented at the 2010 ACR congress. This is not a complete list of all tocilizumab-related abstracts presented at the congress, but includes a range of both Roche- and/or Chugai- sponsored abstracts as well as non-sponsored/investigator-initiated abstracts that have been submitted independently.